Noxopharm Limited (ASX:NOX)

Australia · Delayed Price · Currency is AUD

0.0750

+0.0020 (2.74%)

Jun 22, 2026, 12:44 PM AEST

15.38% (1Y)

Market Cap	22.43M -0.3%
Revenue (ttm)	3.40M +44.8%
Net Income	-5.49M
EPS	-0.02
Shares Out	307.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,570
Open	0.0750
Previous Close	0.0730
Day's Range	0.0750 - 0.0750
52-Week Range	0.0430 - 0.1350
Beta	0.02
Analysts	Buy
Price Target	1.50 (+1,900.0%)
Earnings Date	Aug 28, 2026

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol NOX

Full Company Profile

Financial Performance

In fiscal year 2025, Noxopharm's revenue was 2.82 million, an increase of 17.52% compared to the previous year's 2.40 million. Losses were -4.88 million, 36.5% more than in 2024.

Financial Statements